Počet záznamů: 1  

Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis

  1. 1. 0477084 - MBU-M 2018 RIV GB eng J - Článek v odborném periodiku
    Stojanovic, I. - Dimitrijevic, M. - Vives-Pi, M. - Mansilla, M.J. - Pujol-Autonell, I. - Rodriguez-Fernandez, S. - Pálová-Jelínková, L. - Funda, David P. - Gruden-Movsesijan, A. - Sofronic-Milosavljevic, L. - Hilkens, C.M.U. - Martínez-Cáceres, E. - Miljković, D.
    Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis.
    Current Pharmaceutical Design. Roč. 23, č. 18 (2017), s. 2623-2643. ISSN 1381-6128
    Grant CEP: GA ČR GA15-24487S
    Institucionální podpora: RVO:61388971
    Klíčová slova: Cell-based tolerogenic therapy * regulatory T cells * tolerogenic dendritic cells
    Kód oboru RIV: EE - Mikrobiologie, virologie
    Obor OECD: Microbiology
    Impakt faktor: 2.757, rok: 2017

    Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
    Trvalý link: http://hdl.handle.net/11104/0273483